Tsis ntev los no, ntau tus neeg mob tau qhia cov ntaub ntawv online txog kev tsis txaus thiab cov khoom lag luam ntawm cov tshuaj nephropathy budesonide enteric-coated capsules.
Hauv kev teb, Yunding Xinyao tau hais rau xov xwm tias budesonide enteric-coated capsules tau suav nrog hauv National Reimbursement Drug List txij thaum Lub Ib Hlis 2025, ua rau muaj kev thov nce ntxiv. Txawm li cas los xij, muaj peev xwm tsim tau tsawg tau ua rau muaj peev xwm tsis txaus uas yuav ua tsis tau raws li qhov xav tau ntawm cov neeg mob hauv lub tebchaws.Lub Ob Hlis xyoo no, lub tuam txhab tau xa daim ntawv thov mus rau Center for Drug Evaluation (CDE) ntawm National Medical Products Administration (NMPA) rau kev nthuav dav kev tsim khoom thiab tam sim no tseem tab tom tos kev tshuaj xyuas los ntawm cov cai tswj hwm tshuaj.
Raws li lub ntiaj teb thawj etiological kev kho mob rau IgA nephropathy, budesonide enteric-coated capsules yog ib qho kev tiv thaiv kab mob tiv thaiv kab mob rau lub plab hnyuv mucosal B hlwb.
Siv ib qho tshwj xeeb dual qeeb-tso tawm thiab txuas ntxiv-tso tawm qauv thev naus laus zis, cov tshuaj xa budesonide tshwj xeeb rau mucosal B hlwb hauv lub davhlau ya nyob twg ileum, suav nrog Peyer's thaj ua rau thaj. Tom qab capsule dissolution, peb-txheej coated pellets tso tawm budesonide tsis tu ncua thiab tsis tu ncua nyob rau hauv ib tug siab concentration nyob rau hauv tag nrho cov hom phiaj.Qhov no txo cov zus tau tej cov galactose-deficient IgA1 antibodies (Gd-IgA1), uas ua rau IgA nephropathy, yog li cuam tshuam nyob rau hauv lub upstream pathogenesis agaticev.
